Opinion|Videos|July 16, 2024
Navigating Biosimilar Uptake in New Patients
The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you direct new-start patients to a biosimilar? What about switching?
- Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
3
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
4
MDS/MPN Response Criteria Tied to Survival
5